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Background: Endothelial dysfunction, characterized by diminished endothelial progenitor cell (EPC) function and
ﬂow-mediated vasodilation (FMD), is a clinically signiﬁcant feature of heart failure (HF).Mesenchymal stem cells
(MSCs), which have pro-angiogenic properties, have the potential to restore endothelial function. Accordingly,
we tested the hypothesis that MSCs increase EPC function and restore ﬂow-mediated vasodilation (FMD).
Methods: Idiopathic dilated and ischemic cardiomyopathy patients were randomly assigned to receive autolo-
gous (n = 7) or allogeneic (n = 15) MSCs. We assessed EPC-colony forming units (EPC-CFUs), FMD, and
circulating levels of vascular endothelial growth factor (VEGF) in patients before and three months after MSC
transendocardial injection (n = 22) and in healthy controls (n = 10).
Findings: EPC-colony forming units (CFUs)weremarkedly reduced inHF compared to healthy controls (4± 3 vs.
25± 16 CFUs, P b 0.0001). Similarly, FMD%was impaired in HF (5.6± 3.2% vs. 9.0 ± 3.3%, P= 0.01). Allogeneic,
but not autologous,MSCs improved endothelial function threemonths after treatment (Δ10±5 vs.Δ1±3 CFUs,
P=0.0067;Δ3.7± 3% vs.Δ-0.46± 3% FMD, P= 0.005). Patients who received allogeneicMSCs had a reduction
in serum VEGF levels three months after treatment, while patients who received autologous MSCs had an
increase (P = 0.0012), and these changes correlated with the change in EPC-CFUs (P b 0.0001). Lastly, human
umbilical vein endothelial cells (HUVECs) with impaired vasculogenesis due to pharmacologic nitric oxide
synthase inhibition, were rescued by allogeneic MSC conditioned medium (P = 0.006).
Interpretation: These ﬁndings reveal a novel mechanism whereby allogeneic, but not autologous, MSC adminis-
tration results in the proliferation of functional EPCs and improvement in vascular reactivity, which in turn re-
stores endothelial function towards normal in patients with HF. These ﬁndings have signiﬁcant clinical and
biological implications for the use of MSCs in HF and other disorders associated with endothelial dysfunction.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Heart failure (HF) remains a leading cause of morbidity and mortal-
ity in the United States andworldwide (Go et al., 2014; Bui et al., 2011).
The failing circulation is characterized not only by depressed cardiac
function, but also by endothelial dysfunction (Blum, 2009). Endothelial
dysfunction—deﬁned by impaired ﬂow-mediated vasodilation (FMD)
and endothelial progenitor cell (EPC) function—produces increased sys-
temic vascular resistance, which augments stress on the failing heart,Institute, University of Miami
Room 908, 1501 NW 10th Ave.,
. This is an open access article underand contributes to HF symptomology (Marti et al., 2012). Endothelial
dysfunction is also a crucial component of the pathophysiology of nu-
merous cardiovascular (CV) disorders and manifests in patients with
CV risk factors such as atherosclerosis, hypertension, and diabetes
mellitus (Schulman et al., 2006). Moreover, EPCs regulate the health of
the vasculature by incorporating into the endothelium, replacing in-
jured endothelial cells, and secreting angiogenic factors that activate
mature endothelial cells (Zampetaki et al., 2008). Notably, HF patients
have decreased circulating EPC levels and bioactivity (Schmidt-Lucke
et al., 2005).
Mesenchymal stem cells (MSCs), under evaluation as a regenerative
therapeutic approach for HF (Hare et al., 2012; Heldman et al., 2014;
Karantalis and Hare, in press), have the potential for clinical beneﬁt in
CV disease by virtue of their antiﬁbrotic, anti-inﬂammatory, and pro-
angiogenic properties (Williams and Hare, 2011; Cao et al., 2015), andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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et al., 2010; Chen et al., 2008). Given this capacity of MSCs and the
role of impaired EPCs in human HF (Werner et al., 2005; Shantsila
et al., 2007a), we hypothesized that MSCswould stimulate the bioactiv-
ity of circulating EPCs and improve endothelial function in the failing
circulation. Accordingly, we tested the hypothesis that MSCs stimulate
EPC function and augment vascular relaxation in patients with HF due
to either idiopathic dilated cardiomyopathy (DCM) or ischemic cardio-
myopathy (ICM). Our results show that allogeneic, but not autologous,
MSCs improve EPC bioactivity and endothelial function in HF patients,
regardless of the etiology. These ﬁndings demonstrate a novel clinical
beneﬁcial effect of allogeneic MSCs transplantation in patients with HF
and have implications for all disorders associated with endothelial
dysfunction.
2. Materials and Methods
2.1. Experimental Design
The objective of this study was to analyze the change in endothelial
functionmeasured by EPC-CFUs and FMD% after either allogeneic or au-
tologous MSC administration. Patients enrolled in ongoing clinical trials
with both ischemic and non-ischemic cardiomyopathy were recruited
to this endothelial trial. Power calculations were performed for both
our primary endpoint, FMD%, and our secondary endpoint, EPC-CFUs.
In order to study the response from autologous versus allogeneic pa-
tients for both endpoints, we needed ﬁve autologous and ﬁve allogeneic
subjects to be able to reject the null hypothesis. Data was collected at
baseline and 3 months post-treatment, and treatment group was
blinded.
2.2. Study Population
This study entitled “Studying Endothelial Function and Endothelial
Progenitor Stem Cells' Colonies Before and After Heart Mesenchymal
Stem Cell Transplantation” is a University of Miami Institutional Review
Board approved endothelial trial (#20110543). The HF patients recruit-
ed for this study are enrolled in POSEIDON-DCM (NCT01392625), “A
Phase I/II, Randomized Pilot Study of the Comparative Safety and
Efﬁcacy of Transendocardial Injection of Autologous Mesenchymal
Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients with
Nonischemic Dilated Cardiomyopathy” (Mushtaq et al., 2014) and in
TRIDENT (NCT02013674), “The Transendocardial Stem Cell Injection
Delivery Effects onNeomyogenesis Study”. In PODEIDON-DCM, patients
were randomized to receive by transendocardial delivery either 100
million autologous or allogeneic MSCs. Autologous MSCs were derived
from the patient's bone marrow (iliac crest aspiration) 4–6 weeks
before cardiac catheterization. In the TRIDENT study, ICM patients
were randomized to receive either 20 or 100 million allogeneic MSCs
transendocardially. Allogeneic MSCs weremanufactured by the Univer-
sity of Miami Cell Manufacturing Program (Da Silva and Hare, 2013).
Healthy subjects (n = 10) were enrolled ranging in ages from 22–
58 years and both genders. All subjects provided written informed
consent.
2.3. Cell Characterization
Both autologous and allogeneic MSCs were manufactured by the
Foundation for Accreditation of Cellular Therapy (FACT)-accredited
Good Manufacturing Practice (GMP) Cell Production Facility at the In-
terdisciplinary Stem Cell Institute, University of Miami Miller School of
Medicine, as previously described (Hare et al., 2012; Da Silva and
Hare, 2013). Cells were released for patient administration after meet-
ing the following criteria: negative for mycoplasma via polymerase
chain reaction, ≥70% cell viability, growth assay via colony forming
unit-ﬁbroblasts assay, positive for CD105 (N80%) and negative forCD45 by ﬂow cytometry, and no growth of bacteria. On average, autol-
ogous MSCs were 92.9 ± 3.2% CD105+/CD45−, and the allogeneic
MSCs were 96.4 ± 0.04% CD105+/CD45− (Supplemental Fig. 1).2.4. Endothelial Colony Forming Units (EPC-CFUs)
Peripheral blood samples were obtained from patients before and
three months after MSC injection. EPCs were isolated from samples
using Ficoll-Paque and ﬁve million cells were seeded on 6-well
ﬁbronectin-coated dishes (BD biosciences) in CFU-Hill medium (stem
cell technologies, cat#05900) (Hill et al., 2003; Solomon et al., 2012).
The non-adherent cells were collected 48 h later and one million cells
were seeded on 24-well ﬁbronectin-coated dishes. On day ﬁve, EPC-
CFUs were counted in ﬁve wells and the average was obtained.2.5. Immunoﬂuorescence
Colonies were directly ﬁxed on ﬁbronectin-coated dishes using
4% PFA. Cells were blocked in 10% normal donkey serum/0.3% Triton
X-100/PBS for 1 h and then incubated in anti-CD31 and anti-VEGFR
overnight at 4* (DAKO #235218, Cell Signaling #55B1R). Next, cells
were incubated in Alexa Flour 564 anti-mouse and Alexa Flour 488
anti-rabbit for 45 min at room temperature. Lastly, wells were cover
slipped with Vectashield plus DAPI. Images were obtained using immu-
noﬂuorescent microscopy.2.6. Flow-Mediated Vasodilation (FMD)
Brachial artery diameter measurements and FMD% were performed
in the morning, after an overnight fast. The subjects' right arm was
immobilized in an extended position, and the brachial artery was
scanned via ultrasound 5–10 cm above the antecubital fossa (Hill
et al., 2003; Corretti et al., 2002). A brachial cuff was then inﬂated to a
supra-systolic pressure (40 to 50 mm Hg above systolic pressure) for
5min. Subsequently, the cuff was deﬂated and the brachial artery diam-
eter was recorded for 3 min.2.7. VEGF ELISA
Serum vascular endothelium growth factor (VEGF) levels
(Invitrogen #KHG0111) were measured in DCM patients at baseline
and 6months after allogeneic (n= 6) or autologous (n= 5)MSC treat-
ment. In ICMpatients (n=4), VEGFwasmeasured at baseline and three
months after allogeneic MSC treatment. DCM and ICM patients who re-
ceived allogeneic MSCs were combined and compared to patients who
received autologous. Lastly, VEGF was measured in healthy controls
(n = 9), which provided written informed consent.2.8. Matrigel Assays
Human umbilical vein endothelial cells (HUVECs) were grown to
passage seven in EGM-2 medium (LONZA). Autologous (n= 7) and al-
logeneic (n = 5) donor MSCs were grown to 70% conﬂuence and the
conditioned medium was obtained. Brieﬂy, MSCs were starved in
MEM alpha for 24 h at 5%, the supernatant was collected, centrifuged
at 2000 g for 10 min, and stored at −20° until use. 50,000 HUVECs
were plated on Matrigel (BD Biosciences) in 24-well plates and pre-
treated with 15 μM L-NAME (Cayman Chemical #80210) dissolved in
alpha-MEM (GIBCO) for 45min. 80% of eitherMSC conditionedmedium
(MSC-CM) or plain MEM alpha was added to respective treatment
wells, and L-NAME was kept in the medium. After 6 h, six pictures per
well were taken and Image J was used to analyze vascular index (tube
length × tube number).
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To assess the difference between autologous and allogeneic groups,
an unpaired, two-tailed t-test was used. To measure the difference be-
fore and after treatment in each group, both a paired, two-tailed t-test
and a one-way ANOVA was utilized. Correlations were measured using
Pearson correlation, assuming a Gaussian distribution. Data are present-
ed as mean and standard deviation of the mean. Both D'Agostino-Pear-
son omnibus normality test and Shapiro–Wilk normality tests were run
to measure within-group variability on all data (only signiﬁcant differ-
ences were reported as D'Agostino-Pearson). Lastly, differences be-
tween groups regarding gender, race/ethnicity, history of smoking,
and medications were analyzed using a Fisher exact test.3. Results
3.1. Baseline Characteristics
A total of 22 patients were analyzed for this study. Allogeneic (n =
15) and autologous (n=7)MSCswere administered transendocardially.
Baseline characteristics of the study subjects are summarized in Table 1.
PatientswithDCMwere evenly distributed for both age and sex (P=NS,
ANOVA). Additionally, there was no difference in age between ICM and
DCMpatients receiving allogeneicMSCs (P=NS, ANOVA); however pa-
tients with ICMwere older than patients with DCM receiving autologous
MSCs (P b 0.01, ANOVA). ThereweremoreWhite/Hispanic patientswith
DCM compared to all other treatment groups (P = 0.022, Fisher exact
test). Additionally, patients with DCM who received allogeneic MSCs
had higher cholesterol than patients with ICM who received allogeneic
MSCs (P b 0.05, ANOVA). As expected, there was a signiﬁcant differenceTable 1
Baseline characteristics of patients (n=22) and healthy controls (n=10). Patient data are brok
allogeneic mesenchymal stem cells (MSCs) (n = 9), DCM patients receiving autologous MSCs
*Asterisks next to P values indicate signiﬁcant differences between groups. *Asterisks next to val
controls were left out of Fisher Exact test.
Characteristic DCM allogeneic (n = 9, 27%) DCM autologous (n = 7, 21%
Age — yr.
Median 60 55*
Range 45–70 48–73
Male sex — no. 8 (89%) 6 (86%)
Race/ethnicity
White 8 (89%) 3 (43%)
White/Hispanic 0 (0%) 4 (57%)
Black 1 (11%) 0 (0%)
History of CVD
CAD 1 (11%) 0 (0%)
History of smoking† 4 (44%) 4 (57%)
Blood pressure-mm Hg (systolic/diastolic)
Median 126/77 108/65
Range 108–141/54–91 99–142/59–84
Cholesterol (mg/dL)
Median 202* 175
Range 129–282 112–207
C-reactive protein (mg/mL)
Median 0.3 0.3
3 0.15 N/A
Range 0.2–0.4 0.2–0.5
Medications
ASA/NSAIDS† 5 (56%) 4 (57%)
Beta-blockers† 7 (78%) 7 (100%)
ACE† inhibitors/ARBs 6 (67%) 7 (100%)
Diuretics† 8 (89%) 6 (86%)
Statins† 3 (33%) 3 (43%)
Antiplatelet† 4 (44%) 2 (29%)
Other† 9 (100%) 7 (100%)between groups regarding coronary artery disease (CAD); speciﬁcally, all
patients with ICM had CAD (P = 0.0058).
3.2. EPC-Colony Forming Units (CFUs) and Flow-Mediated Vasodilation
(FMD) in Heart Failure Patients and Healthy Subjects
Patientswith ischemic (n=6) aswell as non-ischemic (n=16) car-
diomyopathy had endothelial dysfunction at baseline, characterized by
a reduced ability to form EPC-CFUs and an impaired FMD response. Spe-
ciﬁcally, patients had decreased EPC-CFU counts compared to healthy
controls (4 ± 3 vs. 25 ± 16, respectively, P b 0.0001, t-test; Fig. 1A) as
well as diminished FMD% (5.6 ± 3.2 vs. 9.0 ± 3.3, respectively, P =
0.01, t-test; Fig. 1B).
Patientswere further analyzed by disease etiology. Therewas no dif-
ference in EPC-CFUs or FMD% comparing patients with DCM (n = 16)
versus ICM (n = 6) at baseline (3 ± 3 vs. 6 ± 1 CFUs, respectively;
5.9 ± 3.6 vs. 5.1 ± 2.0%, respectively; Figs. S2A and S3A). Additionally,
there was no difference at baseline in EPC-CFUs comparing DCM
patientswho received allogeneicMSCs (n=9) toDCMpatientswho re-
ceived autologousMSCs (n=7) (3±2 vs. 5±4, respectively; Fig. S2B).
However, DCM patients receiving autologous MSCs had a higher FMD%
at baseline compared to DCM patients receiving allogeneic MSCs (8.3 ±
3.5 vs. 4 ± 2.4, P= 0.011, t-test; Fig. S3B).
Moreover, we did a sub-analysis of the patients that received alloge-
neic MSCs. At baseline, patients with ICM (n = 6) had more EPC-CFUs
than patients with DCM (n = 9) (6 ± 1 vs. 3 ± 2, P = 0.0011, t-test),
and there was no difference in FMD% (5.1 ± 2 vs. 2.4 ± 5.7, P =
0.3742, t-test). Despite ICM patients having more EPC-CFUs at baseline,
the improvement from baseline to 3 months post-injection was the
same (11 ± 8 vs. 10 ± 4 DCM, P = 0.6195, t-test). Comparably, there
was no difference in the change in FMD % from baseline to 3 monthsen down by etiology and cell treatment: Dilated cardiomyopathy (DCM)patients receiving
(n = 7) and ischemic cardiomyopathy (ICM) patients receiving allogeneic MSCs (n = 6).
ues indicate signiﬁcant difference between noted groups (ANOVA). † indicates that healthy
) ICM allogeneic (n = 6, 18%) Healthy controls (n = 10, 33%) P-values
71* 44 *b0.01
65–75 22–58
6 (100%) 7 (70%) 0.419
6 (100%) 7 (70%) 0.114
0 (0%) 3 (30%) *0.022
0 (0%) 0 (0%) 0.451
6 (100%) 0 (0%) **0.0058
4 (67%) 0 (0%) 0.689
113/70 118/67 0.979
85–134/53–76 111–130/59–90
147* N/A * b 0.05
129–178 N/A
0.923
0.1–0.6 N/A
5 (83%) 0 (0%) 0.5
6 (100%) 0 (0%) 0.204
6 (100%) 1 (10%) 0.166
4 (67%) 0 (0%) 0.0814
6 (100%) 1 (10%) *0.03
3 (50%) 0 (0%) 0.707
6 (100%) 0 (0%) NS
Fig. 1. Endothelial function in patients with heart failure, including dilated and ischemic cardiomyopathy. (A) Patients (n= 22) have impaired endothelial progenitor cell-colony forming
units (EPC-CFUs) compared to healthy controls (n=10, *Pb 0.0001, t test). (B) Patients (n=22) have reducedﬂow-mediated vasodilation (FMD%) compared to healthy controls (n=10,
†P= 0. 01, t-test).
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MSCs (3.4 ± 2.86 vs. 4.18 vs. 3.16, P = 0.6280, t-test).
3.3. EPC-CFUs in Heart Failure Patients Treated With MSCs
Patients were assessed for EPC-CFUs before and 3 months after MSC
treatment. Patients who received allogeneic MSCs had a signiﬁcant im-
provement in the number of EPC-CFUs post-treatment (Δ10 ± 5,
P b 0.0001, t-test; Fig. 2A). On the other hand, patients who received au-
tologous MSCs showed no improvement (Δ1 ± 3, P = NS, t-test;
Fig. 2B). Moreover, we compared allogeneic versus autologous MSC
treatment, and allogeneicMSCswere superior in stimulating EPC colony
formation (P= 0.0067, t-test).
We also compared allogeneic treatment versus autologous treat-
ment in DCM patients. 3 months post-injection, DCM patients who re-
ceived allogeneic MSCs had signiﬁcantly higher EPC-CFUs compared to
patients who received autologous MSCs (12 ± 4 vs. 6 ± 5, P = 0.015,
t-test; Fig. S2C). Accordingly, DCM patients who received allogeneic
MSCs had a signiﬁcantly greater positive change in EPC-CFUs frombase-
line to 3months post-injection compared toDCMpatientswho received
autologous MSCs (10 ± 4 vs. 1 ± 3, respectively, P b 0.0001, t-test;
Fig. S2D).
EPC-CFUs were examined for morphology. EPCs from HF patients
had disorganized and incomplete colony formation (Fig. 2C and D),
resulting in clusters that failed to form functional colonies. Three
months after allogeneic MSC treatment, patient colonies were orga-
nized and healthy in appearance (Fig. 2E and F). Importantly, we
found that these colonies were positive for the endothelial cell markers
CD31/PECAMandVEGFR (Fig. 2G). Together, theseﬁndings suggest that
transendocardial MSC therapy stimulates EPC bioactivity in patients
with HF of both ischemic and non-ischemic etiology.
3.4. FMD in Heart Failure Patients Treated With MSCs
All patients were evaluated using brachial artery FMD before and 3
months after MSC injection. Patients who received allogeneic MSCs
had a dramatic improvement in FMD% (Δ3.7 ± 3%, P= 0.0002, t-test;
Fig. 3A). In contrast, patients who received autologousMSCs had no im-
provement and the majority of patients worsened 3 months post-
treatment (Δ-0.46 ± 3%, Fig. 3B).
We next analyzed the difference between treatment with autolo-
gous MSCs and allogeneic MSCs. There was a striking difference
between the two cell types (P= 0.005, t-test), suggesting that autolo-
gous MSCs do not restore endothelial function in this patient popula-
tion. We also assessed the correlation between EPC-CFUs and FMD% in
all patients and found a highly signiﬁcant correlation between ΔFMD%
and ΔEPC-CFUs (P= 0.0004, R= 0.68, Pearson correlation; Fig. 3C).Lastly, we analyzed DCMpatients only, comparing autologous vs. al-
logeneic treatment. While patients who received allogeneic MSCs had
similar FMD% compared to patients who received autologous MSCs
3 months after treatment (7.4 ± 4.7 vs. 7.9±3.1; Fig. S2C), patients
who received allogeneic MSCs had a greater change from baseline to
3months post-injection compared to patients who received autologous
MSCs (3.8 ± 2.6 vs. 0.7 ± 2.9, P = 0.042, t-test; Fig. S3D). Notably, the
majority of patients receiving autologous MSCs had no improvement
or worsened, while all allogeneic patients improved (P = NS vs.
P b 0.0001, t-test).
3.5. Vascular Endothelial Growth Factor (VEGF) in Patients Receiving
Autologous and Allogeneic MSCs
Wemeasured circulating VEGF levels in patients and healthy control
serum. At baseline, patients had profoundly elevated circulating VEGF
compared to controls (1130.3 ± 803.3 vs. 2.0 ± 5.9 pg/mL, P =
0.0009, t-test; within-group, P = 0.21, P b 0.001 respectively,
D'Agostino-Pearson omnibus normality test; Fig. 4A). Allogeneic MSCs
reduced VEGF levels (−547.5 ± 350.8 pg/mL, P = 0.0015, t-test;
within-group P = 0.96, D'Agostino-Pearson omnibus normality test),
while patients who received autologous MSCs had an increase in VEGF
levels (814.1 ± 875.8 pg/mL, Fig. 4B). Furthermore, there was a signiﬁ-
cant difference between patients who received allogeneic MSCs versus
patients who received autologous MSCs (P= 0.0012, t-test; Fig. 4B).
VEGF levels correlated with EPC-CFUs (P = 0.026, R = −0.421,
Pearson correlation; Fig. 4C). Evenmore striking, there was a signiﬁcant
correlation between the change in VEGF and the change in EPC-CFUs
from baseline to 3 months post-treatment (R=0.863, P b 0.0001, Pear-
son correlation; Fig. 4D). Notably, high levels of VEGF correlated with
low levels of EPCs, evidenced by the autologous group. Conversely,
lower levels of VEGF correlated with high levels of EPC-CFUs, illustrated
by the allogeneic group. Taken together, these data demonstrate that al-
logeneic MSCs stimulate EPC mobilization and suppress compensatory
elevations in circulating VEGF concentrations.
3.6. Autologous and Allogeneic MSC Paracrine Effect on Endothelial Cells
Human umbilical vein endothelial cells (HUVECs), pre-treated with
L-NAME to block endogenous nitric oxide (NO) synthesis, were subse-
quently treated with autologous or allogeneic MSC-conditioned media
(CM), and vasculogenesis was examined in Matrigel assays
(Fig. 5A–D). HUVECs treated with L-NAME exhibited severely im-
paired vasculogenesis (Fig. 5B), evident by their depressed vascular
index (305.2 ± 196.8 vs. 1170.9 ± 352.6, P = 0.02, t-test; Fig. 5E).
Only the addition of allogeneic MSC-CM prevented the L-NAME-
induced impairment in vasculogenesis (vascular index 305.2 ±
196.8 L-NAME alone vs. 1113.4 ± 296.2 L-NAME + Allogeneic
Fig. 2.Endothelial colony formingunits in heart failure patients treatedwith either allogeneic or autologousmesenchymal stemcells (MSCs). (A) Patients treatedwith allogeneicMSCs had
a signiﬁcant improvement in endothelial progenitor cell-colony forming units (EPC-CFUs) 3 months post-treatment (n = 15, *P b 0. 0001, t-test). (B) Patients treated with autologous
MSCs had no change in EPC-CFUs post-treatment (n= 7, P=NS, t-test). (C–F) Representative EPC-CFUs plated on ﬁbronectin for 5 days before (C, D) and after (E, F) MSC administration
(magniﬁcation 20×). (G) Colonies are positive for the endothelial cell markers CD31 (red) and VEGFR (green) (magniﬁcation 20×).
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that allogeneic MSCs are able to restore the vascular potential of
endothelial cells.
4. Discussion
Patients with cardiomyopathy of ischemic or non-ischemic etiology
manifest endothelial dysfunction, characterized by reduced EPC colonyformation, impaired FMD, and elevated VEGF levels. The major new
ﬁnding of this study is that MSC administration to these patients stimu-
lates EPC bioactivity and restores ﬂow-mediated vasodilation towards
normal. Importantly, the ability of allogeneic MSCs greatly exceeded
that of autologous MSCs in restoring endothelial function, enhancing
EPC colony formation, and suppressing VEGF levels. Together these
ﬁndings offer major new clinical insights into the bioactivity of MSCs,
suggest a novel therapeutic principle for disorders characterized by
Fig. 3. Flow-mediated vasodilation (FMD) measurements before and after mesenchymal stem cell (MSC) treatment. (A) Patients treated with allogeneic MSCs had an increase in FMD%
3 months post-injection (n = 15, *P = 0.0002, t-test). (B) Patients treated with autologous MSCs had no signiﬁcant difference in FMD% 3 months post-injection (n= 7, P = NS, t-test).
(C) There is a strong correlation between the absolute change in FMD% and the absolute change in endothelial progenitor cell-colony forming units (EPC-CFUs) from baseline to 3months
post-MSC injection in all patients (*P = 0.0004, R= 0.68, Pearson correlation).
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neic vs. autologous MSC cell therapy.
There is an increasing awareness of the central role endothelial dys-
function plays in CV disorders. Low numbers of EPC-CFUs strongly cor-
relate with endothelial dysfunction (Werner et al., 2007) and are
associatedwith a high Framingham risk score for adverse CV health out-
comes (Hill et al., 2003). Furthermore, circulating EPC levels predict CV
events—speciﬁcally in patients with coronary artery disease, heart fail-
ure, and angina (Schmidt-Lucke et al., 2005; Hill et al., 2003; Shantsila
et al., 2007b). In addition, elevated levels of circulating VEGF are linked
to endothelial dysfunction and HF (Chin et al., 2002; Tsai et al., 2005). In
this regard, Eleuteri et al. demonstrated that elevated levels of VEGF cor-
related with HF disease progression (Eleuteri et al., 2011). Moreover,
Wei et al. investigated circulating EPCs and VEGF levels in patients
with cerebral aneurysm and found that decreased levels of circulating
EPCs and increased levels of plasma VEGF were associated with chronic
inﬂammation in the vascular walls of cerebral arteries and the develop-
ment of cerebrovascular abnormalities leading to aneurysm formation
and rupture (Wei et al., 2011). Thus, endothelial dysfunction is a central
feature of CVdisease, andmay represent a powerful surrogatemarker in
the development of new treatments for CV disease.
MSCs are adult stem cells that are prototypically found in bonemar-
row and have the capacity to differentiate into multiple cell types
(Williams andHare, 2011). Importantly, they stimulate the proliferation
and differentiation of endogenous precursor cells and play a crucial role
in maintaining stem cell niches (Williams and Hare, 2011). In addition,
MSCs secrete paracrine factors that participate in angiogenesis,
cardiomyogenesis, neovascularization, stimulation of other endogenous
stem cells, and regulation of the immune system (Gomes et al., 2013;
Gnecchi et al., 2008). While MSCs are known to stimulate cardiac pre-
cursor cells and cell cycle activity in the heart (Hatzistergos et al.,
2010), their role in stimulating other endogenous precursor populations
has heretofore been unknown. Here we report that MSCs stimulatedendogenous EPC activation, increasing the number and quality of func-
tional EPCs. These ﬁndings suggest that augmentation of EPCs may rep-
resent a novel mechanism of action by which MSCs exert favorable
biological effects.
Over the last decade, there has been an emerging interest in the use
of MSCs in CV disorders (Karantalis and Hare, in press; Telukuntla et al.,
2013). Clinical trials have demonstrated a major safety proﬁle for MSC
administration, and suggested efﬁcacy in patients with HF (Hare et al.,
2012; Telukuntla et al., 2013); however, underlying mechanism(s) of
action continue to be vigorously debated. Our ﬁnding that allogeneic
MSC injections in patients with both ischemic and non-ischemic HF re-
sults in an improvement in endothelial function, speciﬁcally by restor-
ing EPC function and FMD and reducing VEGF levels towards normal,
offers a major new insight into the mechanisms of action of MSCs. In
the studypopulation, increased serumVEGF correlatedwith diminished
EPC-CFUs, consistentwith the idea that VEGF plays a compensatory role,
a ﬁnding also reported in patients with cerebral aneurysm (Wei et al.,
2011). This is also supported by the study of Vasa et al. which showed
a diminished response of EPCs to VEGF in patients with CAD (Vasa
et al., 2001). Moreover, Alber et al. found that a key beneﬁcial effect of
atorvastatin therapy is reducing the levels of plasma VEGF in patients
with CAD (Franz Alber et al., 2002). This coincides with our study
using MSCs, rather than a pharmacological intervention, to decrease
pathologic VEGF and increase endothelial function. Thus our ﬁndings
establish a previously unappreciated therapeutic principle whereby al-
logeneic MSCs can be employed to stimulate EPC bioactivity, improve
arterial physiologic vasodilatory responses, and decrease unfavorable
cytokine mobilization in patients with CV disease and other disorders
associated with endothelial dysfunction.
We found that allogeneic MSCs restored endothelial function in pa-
tients to a degree greatly exceeding that of autologousMSCs. One possi-
ble explanation for this may be the age of the cells. Recent studies
highlight that MSC's therapeutic function declines as a result of aging
Fig. 4. Serumvascular endotheliumgrowth factor (VEGF) concentration inpatients and controls. (A) Patients (n=14)have a higher level of circulating VEGF compared to controls (n=9)
at baseline (*P = 0.0009, t-test; within-group, P = 0.21, P b 0.001, respectively, D'Agostino-Pearson omnibus normality test). (B) Patients who received allogeneic MSCs (n = 9) had a
decrease in VEGF serum levels post-injection (Δ-547.5 ± 350.8 pg/mL, †P = 0.0015, t-test; within-group P = 0.96, D'Agostino-Pearson omnibus normality test), while patients who re-
ceived autologous MSCs (n = 5) had an increase in serum VEGF post-injection (Δ814.1 ± 875.8), and there was a difference between the groups (†P= 0.0012, t-test). (C) There is a cor-
relation between endothelial progenitor cell-colony forming units (EPC-CFUs) and serum VEGF in patients at both baseline and 3 months post-MSC treatment (R=−0.421, ‡P = 0.026,
Pearson correlation). (D) The change in EPC-CFUs from baseline to 3 months post-treatment strongly correlated with the change in VEGF (R=−0.863,*P b 0.0001, Pearson correlation).
473C. Premer et al. / EBioMedicine 2 (2015) 467–475(Eﬁmenko et al., 2013; Asumda, 2013). Eﬁmenko et al. showed that
adipose-derived MSCs from aged patients with coronary artery disease
have impaired angiogenic potential (Eﬁmenko et al., 2013). Similarly,
Kasper et al. demonstrated that MSC function is altered and diminished
with age, speciﬁcally showing lower actin turnover and therefore de-
creased motility, decreased antioxidant power, decreased responsive-
ness to chemical and mechanical signaling, and increased senescence
(Kasper et al., 2009). Stolzing et al. also reported a decline in “ﬁtness”
as a result of aging, as evidenced by a decline in colony-forming unit-
ﬁbroblasts and increase in reactive oxygen species levels and oxidative
stress (Stolzing et al., 2008). In our study, all allogeneic stem cell donors
were healthy, young donors between the ages of 20 and 35. Patients re-
ceiving their own stem cells not only had underlying chronic diseases,
but also were older (between the ages of 45 and 75). MSC aging may
impair the survival, differentiation, and ability to recruit EPCs to areas
of damage, ultimately reducing their therapeutic efﬁcacy (Asumda,
2013). Additionally, due to underlying patient comorbidities, the autol-
ogousMSCmicroenvironmentmay benegatively altered due to system-
atic inﬂammation. Consistent with this notion, Teraa et al. showed that
systemic inﬂammation affects the bone marrow microenvironment,
disturbing EPC function (Teraa et al., 2013). Although more studies are
necessary to validate that the advantage evident here is due to the
health and age of MSCs, this study supports the encouraging idea of
using “off the shelf” allogeneic MSCs over autologous MSCs.
In this study, we report positive systemic effects from local, cardiac
transendocardial MSC injections. We have previously shown that MSC
engraftment after intramyocardial injection is approximately 10 to
20%, suggesting that these cells migrate and circulate systemically
(Quevedo et al., 2009). MSCs are known to secrete anti-inﬂammatory
factors and cytokines (such as IL-2, TGF-β1, hepatocyte growth factor,
NO, prostaglandin 2, and stromal cell derived factor-1), which canmod-
ulate the mobilization of EPCs from bone marrow (Williams and Hare,2011; Iyer and Rojas, 2008). Additionally, MSCs have been shown to se-
crete paracrine factors that stimulate resident cells (Williams and Hare,
2011). Thus, we propose a potential mechanism whereby allogeneic
MSCs injected into cardiac tissue respond to local microenvironment
cues, thereby secreting anti-inﬂammatory and EPC mobilizing factors
that ultimately improve endothelial function alleviating cardiac stress.
There are several limitations of our study. All ICM patients received
allogeneic MSCs, therefore we were unable to study the effect of autol-
ogous MSCs in this speciﬁc HF population. Additionally, patients who
received autologous MSCs had higher FMD% at baseline compared to
patients who received allogeneic MSCs. Notably, however, all patients
receiving autologous MSCs had lower FMD% post-treatment, highlight-
ing the allogeneic advantage. There was also a signiﬁcantly higher
White/Hispanic population in the DCM autologous group compared to
other treatment groups. Despite this, therewas nodifference in baseline
or treatment response comparing White/Hispanic patients to White
patients (Supplementary Table 1). Furthermore, patients with ICM re-
ceived different total number of cells (either 20 or 100million cells). Re-
gardless, all patients had an improvement in endothelial function and
there was no intergroup variability. Lastly, there was variability within
our control group for circulating VEGF levels. The majority of our con-
trols had too low levels of circulating VEGF to detect, ultimately
highlighting the elevated levels of VEGF evident in HF patients. Despite
these limitations, we are conﬁdent our results provide novel insights
into the positive endothelial function effect of allogeneic MSCs in pa-
tients with HF.
In conclusion, this study demonstrates a potent and clinically rele-
vant efﬁcacy outcome of transendocardial therapy with MSCs in pa-
tients with advanced HF. Allogeneic MSCs restore ﬂow mediated
brachial artery dilatation, EPC bioactivity, and VEGF levels towards nor-
mal. As abnormalities in the vascular function of patients with CV dis-
ease is shown to be highly predictive of adverse outcomes and disease
Fig. 5. Effect of autologous and allogeneicmesenchymal stem cell (MSC) treatment on vasculogenesis. (A–D) Representative pictures of human umbilical vein endothelial cells (HUVECs)
alone (n= 3), HUVECs with the nitric oxide synthase inhibitor, L-NG-Nitroarginine methyl ester (L-NAME) (n = 3), HUVECs with L-NAME and allogeneic MSC-conditioned media (CM)
(n= 5), and HUVECswith L-NAME and autologousMSC-CM (n= 7) after 6 h onMatrigel (magniﬁcation 10×). (E) L-NAME greatly reduced vascular index (*P b 0.05, ANOVA), and only
allogeneic-CM restored it (*P b 0.05, ANOVA).
474 C. Premer et al. / EBioMedicine 2 (2015) 467–475progression, targeting endothelial function is a signiﬁcant therapeutic
strategy. Together, these ﬁndings offer a new mechanism of action un-
derlying potentially clinically relevant responses to the use of allogeneic
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